Sulai Liu

2 clinical trials · Sponsor

Record	Firm	Date
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC (NCT06364007)	Sulai Liu	2024-03-03
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection (NCT05546619)	Sulai Liu	2022-08-01

Every clearance here is in the API, with alerts when new ones post.